Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coramsine in advanced renal cell carcinoma
ACTRN12606000099527Phase 2Not yet recruiting
- Sponsor
- Arovella Therapeutics
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coramsine in renal cell carcinoma (RCC), sponsored by Arovella Therapeutics. Primary endpoint: Overall response rate. Planned start Jun 2006; status: not yet recruiting.
02
Drugs
coramsine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12606000099527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000099527.